| human | Q5 |
| P106 | occupation | researcher | Q1650915 |
| Q33334774 | A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma |
| Q73746425 | A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors |
| Q34750537 | A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas |
| Q35854468 | A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). |
| Q101408447 | Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical Trials |
| Q53208533 | Adverse-event rates: journals versus databases. |
| Q36425904 | Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma |
| Q33710593 | Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N99 |
| Q33391857 | An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. |
| Q36342900 | Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance) |
| Q44470251 | CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study |
| Q47945603 | Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). |
| Q33976797 | Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively |
| Q33341152 | Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor |
| Q55476767 | Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. |
| Q33605194 | Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. |
| Q103811230 | Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) |
| Q33343936 | Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas |
| Q42288486 | Current use and surgical efficacy of laparoscopic colectomy in colon cancer |
| Q31026840 | Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials |
| Q35009894 | Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program |
| Q36233987 | Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial |
| Q30749793 | Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma |
| Q53859315 | Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. |
| Q33363800 | Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial |
| Q35643367 | Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52 |
| Q43937149 | Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer |
| Q33693309 | KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). |
| Q34665492 | Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes |
| Q47556374 | Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials |
| Q38792393 | North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. |
| Q34561850 | Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study |
| Q33947880 | Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147 |
| Q33376153 | Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248. |
| Q37495410 | Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer |
| Q39109076 | Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). |
| Q34560933 | Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer |
| Q39510870 | Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma |
| Q50921097 | Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. |
| Q33997258 | Phase II study of erlotinib in patients with advanced biliary cancer |
| Q33343208 | Phase II trial of gemcitabine in advanced sarcomas |
| Q34606724 | Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. |
| Q34982575 | Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy |
| Q44875561 | Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study |
| Q80196818 | Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer |
| Q77562069 | Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer |
| Q44471651 | Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers |
| Q34615197 | Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention |
| Q33180566 | Rapid reporting and review of an increased incidence of a known adverse event |
| Q93013397 | RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer |
| Q34048813 | Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study |
| Q61893730 | Sorafenib for Advanced and Refractory Desmoid Tumors |
| Q44915664 | Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity |
| Q24797816 | Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: preliminary analyses and treatment recommendations |
Search more.